People
To date, all the major clinical trials of vaccines against COVID-19 have been in adults.
The urgency of 2020 has shone a spotlight on the investment and advances in the U.S. biotech industry over the past decade – and overall, it is looking strong.
Femtech represents significant growth opportunities for biotech companies, but is still under the radar for most investors. None-the-less, pioneering companies are emerging to address this sector’s many underserved needs.
Charles M. Lieber is currently on paid leave from Harvard’s chemistry department after his arrest in January on charges of lying to the U.S. government about funds received from China.
A 41-year-old man from Richland, Wash. was convicted on 47 counts of fraud and drug related charges on Oct. 1, according to the U.S. Justice Department’s Eastern District of Washington.
In the study published October 7th in Science Translational Medicine, Dr. Weiss et al shared that immunocytokines delivered systemically were effective in mice models and a pilot human trial.
10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
There is little doubt that CRISPR gene editing is and will continue to revolutionize biology and medicine. The Nobel Committee confirmed their belief in that by awarding the Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery and development of CRISPR.
Michael Haas, Medasource’s Pharmaceutical & Life Sciences Vertical Director, describes the company as a “national healthcare consulting and project services company.”
PRESS RELEASES